A randomised trial of more than 7,800 African women found that a type of contraceptive injection (intramuscular depot medroxyprogesterone acetate -- DMPA-IM) posed no substantially increased risk of HIV acquisition when compared with a copper intrauterine device (IUD) and a levonorgestrel (LNG) implant. The results of this first ever randomised trial in the area, published in The Lancet, counter 30 years of epidemiology research suggesting a potential association between some types of contraceptives and risk of acquiring HIV.
Duke researchers describe a previously unidentified route for antibodies to be transferred from the mother to the fetus, illuminating a potential way to capitalize on this process to control when and how certain antibodies are shared.
A new study in JNCI Cancer Spectrum finds that dramatic increases in cancer survival in adolescents and young adults are undermined by continuing disparities by race, ethnicity, and socioeconomic status. The patterns here suggest that most of the recent survival increases in this age group were driven by improvements in treatments for HIV/AIDS and related cancers.
The US Preventive Services Task Force (USPSTF) recommends screening for HIV infection in adolescents and adults ages 15 to 65; in those younger or older at increased risk of infection; and in all pregnant people. The USPSTF routinely makes recommendations about the effectiveness of preventive care services and this statement is an update of its 2013 recommendation.
In a new recommendation, the US Preventive Services Task Force (USPSTF) recommends clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to people at high risk of acquiring HIV to decrease their risk of infection with the virus that causes AIDS.
A new study by CUNY SPH researchers found that the adoption of the WHO's 2015 'Treat All' recommendation was followed by large increases in rapid initiation of antiretroviral therapy (ART) in six sub-Saharan African countries.
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA.
Six months ago, a Chinese scientist announced that he had edited the genomes of two babies born last year. The germline edits with CRISPR-Cas9 supposedly changed the CCR5 gene to prevent HIV from invading immune cells. An analysis of records in the U.K. Biobank shows that having two copies of this mutation is associated with a 21% increase in mortality. UC Berkeley researchers caution against germline editing because of the unknown functions of many genes.
Researchers at USC developed a machine learning model of the invisible networks around us including, how viruses interact with proteins and genes in the body. Their work, they believe, can help across the disciplines from the design of future medicines or gene therapies against viruses and diseases like cancer or help understand how to address cyber attacks.